Heplisav B (Hepatitis B Surface Antigen, Cpg 1018)

Heplisav B is indicated for the prevention of hepatitis B virus infection in adults.

• Primary prophylaxis for adults who have not completed a hepatitis B vaccination series.
• Immunization of individuals at increased risk, such as healthcare personnel and people with occupational exposure.
• Protection for travelers to regions where hepatitis B is endemic.
• Use in patients with chronic liver disease or renal failure who require hepatitis B immunity.
• Administration to adults who need rapid seroconversion before potential exposure.
• Vaccination of adults with immunocompromising conditions who may have reduced response to other hepatitis B vaccines.

The safety profile of Heplisav B reflects the typical reactions observed with injectable hepatitis B vaccines.

Common

• Mild to moderate pain, redness, or swelling at the injection site, usually resolving within a few days without intervention.
• Low‑grade fever or chills that may develop within 24 hours after vaccination and generally subside spontaneously.
• Transient fatigue, headache, or muscle aches that are self‑limited and often improve with rest or over‑the‑counter analgesics.
• Slightly elevated liver enzymes detected in routine laboratory testing, which are usually temporary and not associated with clinical hepatitis.
• Mild nausea or gastrointestinal discomfort that may occur shortly after injection and resolves without specific treatment.

Serious

• Immediate hypersensitivity reactions, including anaphylaxis, which can cause hives, respiratory distress, or circulatory collapse and require emergency care.
• Rare neurologic events such as Guillain‑Barré syndrome reported after vaccination, requiring prompt medical evaluation.

Precautions for Heplisav B focus on patient assessment, timing of administration, and monitoring for adverse reactions.

• Verify no prior severe allergic reaction to any component of the vaccine.
• Assess for acute moderate or severe illness; defer vaccination until recovery.
• Consider postponement in pregnant women, as safety data are limited.
• Review immunocompromised status; vaccine may be less effective.
• Counsel patients to remain for observation after injection to detect immediate reactions.
• Avoid concurrent administration with other live vaccines in the same injection site.

Heplisav B may interact with other medicines or vaccines, influencing immune response or safety.

Avoid

• Administration of another hepatitis B vaccine within 4 weeks, which could interfere with immune response.
• Concurrent use of immunosuppressive therapy that may markedly reduce vaccine efficacy.

Use with caution

• Co‑administration with other inactivated vaccines is generally acceptable but monitor for increased local reactions.
• Use in patients receiving anticoagulants; intramuscular injection may increase bleeding risk.
• Consider timing with biologic agents (e.g., TNF‑α inhibitors); schedule vaccination before initiating therapy when possible.
• If patient is on antipyretic or analgesic therapy, timing does not affect immunogenicity, but advise not to exceed recommended doses.